Expression of Bcl-2 and p53 in the colorectal adenoma-carcinoma sequence

被引:22
作者
Hao, XP
Ilyas, M
Talbot, IC
机构
[1] ST MARKS HOSP,ACAD DEPT PATHOL,IMPERIAL CANC RES FUND,COLORECTAL CANC UNIT,HARROW HA1 3UJ,MIDDX,ENGLAND
[2] JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOL MED,CANC GENET & IMMUNOL LAB,OXFORD OX3 9DU,ENGLAND
关键词
Bcl-2; p53; apoptosis; colorectum; carcinogenesis;
D O I
10.1159/000164115
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To evaluate the respective roles of Bcl-2 and p53 during colorectal tumour growth, 73 sporadic adenomas and 54 carcinomas arising in adenomas were studied by immunohistochemistry. Bcl-2 protein was expressed in 72 of 73 (98.6%) adenomas and in 25 of 54 (46.3%) carcinomas, whereas p53 protein expression was found in 18 of 73 (24.6%) adenomas and 23 of 54 (42.6%) carcinomas. Bcl-2 expression was related to the size and increasing severity of dysplasia (p < 0.05), while p53 expression was associated with the degree of dysplasia, but not with size (p < 0.025 and p > 0.10, respectively). Bcl-2 expression in carcinomas arising in adenomas was significantly reduced when compared with the associated adenoma (p < 0.005). However, there was no such difference in p53 expression between carcinomas and associated adenomas. Interestingly, there were inverse correlations between p53 and Bcl-2 expression in both adenomas and carcinomas (p < 0.05 and p < 0.005, respectively). We conclude that increased expression of Bcl-2 in adenomas may imply increasing protection against apoptosis during the progression from mild to severe dysplasia. Reduced expression of Bcl-2 may be due to downregulation by mutant p53 and may mark the point of transition from adenoma to carcinoma.
引用
收藏
页码:140 / 145
页数:6
相关论文
共 38 条
[21]  
Kaklamanis L, 1996, J PATHOL, V179, P10
[22]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[23]   P53 - ONCOGENE OR ANTI-ONCOGENE [J].
LANE, DP ;
BENCHIMOL, S .
GENES & DEVELOPMENT, 1990, 4 (01) :1-8
[24]   Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours [J].
Lipponen, PK ;
Aaltomaa, S ;
Eskelinen, M .
HISTOPATHOLOGY, 1996, 28 (02) :135-140
[25]  
LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41
[26]  
Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7
[27]  
MIYASHITA T, 1995, CELL, V80, P293
[28]  
MIYASHITA T, 1994, ONCOGENE, V9, P1799
[29]   EXPRESSION OF BCL-2 ONCOPROTEIN IN RENAL-CELL TUMORS [J].
PARAF, F ;
GOGUSEV, J ;
CHRETIEN, Y ;
DROZ, D .
JOURNAL OF PATHOLOGY, 1995, 177 (03) :247-252
[30]   IMMUNOHISTOCHEMICAL DETECTION OF P53-PROTEINS AND BCL-2-PROTEINS IN NON-HODGKINS-LYMPHOMA [J].
PEZZELLA, F ;
MORRISON, H ;
JONES, M ;
GATTER, KC ;
LANE, D ;
HARRIS, AL ;
MASON, DY .
HISTOPATHOLOGY, 1993, 22 (01) :39-44